2.3 Conclusions and Results
According to the findings from serum protein electrophoresis, protein immunofixation, bone marrow biopsy, and other relevant examinations, a definitive diagnosis of multiple myeloma was established (high-risk group, DS stage II, R-ISS stage III). Treatment principles were outlined as follows: 1. Due to the patient’s young age, targeted therapy for the underlying disease was initiated promptly, aiming for a deep response within four cycles, followed by hematopoietic stem cell transplantation. 2. Given the elevated triglycerides, treatment included fenofibrate, elotuzumab, and plasma exchange therapy. During the treatment process, after plasma exchange, the patient underwent the PCD regimen, supplemented with lipid-lowering measures, hydration, alkalization, liver protection, and symptomatic supportive care. Subsequently, there was a noticeable improvement in symptoms, leading to discharge.